3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Expanded_access
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Cholangiocarcinoma
3
Liver Neoplasms
2
Biliary Tract Neoplasms
2
Acrocephalosyndactylia
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
40
Cisplatin
24
Capecitabine
21
Fluorouracil
19
Oxaliplatin
17
Leucovorin
14
pembrolizumab
9
Irinotecan
8
Radiotherapy
7
Erlotinib Hydrochloride
7
durvalumab
6
Sorafenib
4
Magnetic Resonance Spectroscopy
4
Carboplatin
4
trametinib
3
Trastuzumab
3
Photochemotherapy
3
Long-Term Synaptic Depression
3
Interleukin-12 Subunit p35
3
Filgrastim
3
Dihematoporphyrin Ether
3
Dexamethasone
3
Chemotherapy, Adjuvant
3
trifluridine tipiracil drug combination
2
tivozanib
2
tislelizumab
2
spartalizumab
2
regorafenib
2
olaparib
2
dehydroftorafur
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bile Duct Neoplasms
×
derazantinib
×
Clear all
NCT03230318
2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2
Completed
148 enrolled
15 charts